Test Price
800 AED✅ Home Collection Available
JAK2 V617F Quantitative Mutation Analysis in UAE | 800 AED
Executive Summary & Core Metrics
Test Overview & Methodology
Quantitative Detection of the JAK2 V617F Driver Mutation
The JAK2 V617F quantitative mutation test precisely measures the allele burden of the acquired JAK2 V617F mutation, the hallmark driver of Philadelphia‑negative myeloproliferative neoplasms (Ph‑ MPNs). This high‑precision molecular assay is essential for diagnosing polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), and for monitoring minimal residual disease during treatment. Quantitative allele burden data guides risk stratification and therapeutic decisions, including the need for cytoreductive therapy.
| Parameter | Our Test (JAK2 V617F qPCR) | Closest Alternative (NGS Panel) |
|---|---|---|
| Methodology | Real‑Time PCR (qPCR) with allele‑specific probes | Next‑Generation Sequencing (targeted panel) |
| Analytical Sensitivity | 1% mutant allele (LOQ) | ~5% mutant allele (varies by sequencing depth) |
| Clinical Turnaround | 3–4 working days | 7–14 days |
| Quantitative Range | 0.1% – 100% allele burden (linear dynamic range) | Semi‑quantitative (relative read counts) |
| Regulatory Accreditation | DHA‑approved, ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) | Variable by laboratory |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
“As a clinical geneticist, I recognise that molecular testing for the JAK2 V617F mutation provides critical diagnostic clarity for patients presenting with unexplained erythrocytosis, thrombocytosis, or splenomegaly. This quantitative assay not only confirms the diagnosis but also tracks disease evolution over time. I always emphasise that the result must be interpreted alongside the full blood count, peripheral smear, and clinical history to avoid misclassification. Patients should discuss their allele burden trajectory with their haematologist to tailor surveillance and therapy appropriately.”
Medication Advisory
Do not discontinue prescribed medication (especially aspirin, hydroxyurea, or anticoagulants) without consulting your doctor. Abrupt cessation of cytoreductive or anti‑thrombotic therapy can provoke thrombotic events, haemorrhagic complications, or rebound disease progression. Always involve your haematologist before making any changes to your regimen.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Active infection or cellulitis at the venepuncture site; severe uncorrected coagulopathy (INR >2.0, platelets <20×10⁹/L); inability to provide informed consent.
- Red Flags – seek immediate medical attention if after sample collection you experience: fever >38.5°C, expanding haematoma, severe pain, bleeding that does not stop with sustained pressure, or any sign of systemic infection.
Patient FAQ & Clinical Guidance
1. What is the JAK2 V617F mutation test and why has my doctor ordered it?
This molecular test detects and quantifies the specific acquired mutation in the JAK2 gene that drives myeloproliferative neoplasms such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Your doctor orders this test to confirm a suspected MPN diagnosis, distinguish it from reactive conditions, and establish a baseline allele burden for future monitoring.
2. Why is JAK2 V617F testing essential for polycythemia vera and essential thrombocythemia?
The JAK2 V617F mutation is present in approximately 95% of polycythemia vera cases and 50–60% of essential thrombocythemia and primary myelofibrosis cases. Positive identification provides a clonal marker that confirms the diagnosis, guides prognosis, and helps select targeted therapies. A quantitative result enables tracking of molecular response to treatment over time.
3. How should I prepare for the JAK2 V617F blood test and when will I receive my results?
No fasting or special preparation is required. A standard peripheral venous blood sample is collected by our trained phlebotomist either at your home or in our facility. Results are reported within 3–4 working days. Your quantitative allele burden percentage will be available through our secure patient portal, followed by a complimentary telephone consultation with a DHA‑licensed clinician to explain the findings.
UAE Regulatory & Data Privacy Adherence
Data Protection & Legal Compliance
Your genetic data is protected under Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent procedures comply with Federal Decree‑Law No. 4 of 2016 on Medical Liability. All laboratory processes are ISO 9001:2015 accredited (Cert: INT/EGQ/2509DA/3139) and subject to regular audit by the Dubai Health Authority. No genetic information is shared with third parties without your explicit written consent.
Clinical & Logistical Metadata
| Test Name | JAK2 V617F Quantitative Mutation Analysis |
| Price (AED) | 800 |
| Turnaround Time | 3–4 working days |
| Sample Type / Matrix | Peripheral whole blood – VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily from 8 AM to 11 PM |
| Methodology Used | Real‑Time PCR (qPCR) with allele‑specific probes |
| ICD-10-CM Code | D45, D75.A, D47.4 |
| LOINC Code | 91062-1 |
| DHA Facility License & Laboratory Address | DHA Facility License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians